MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication

    T. Denne (Mission Viejo, USA)

    Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…
  • 2025 International Congress

    Medication Error Reduction Strategies in an In-patient Multimodal Intensive Neurorehabilitation and Care (i-MINC) Program

    N. Yousefzadeh, L. Hom, A. Defrank, M. Mccrossin, L. Rubin (Glen Cove, USA)

    Objective: To evaluate medication safety strategies implemented to reduce medication errors in an i-MINC Program Background: Medication mismanagement may lead to critical patient harm in…
  • 2025 International Congress

    Identification of Metabolomic & Proteomic Panels for Parkinson’s Disease progression Diagnosis

    A. Galal, A. Moustafa, M. Salama (Cairo, Egypt)

    Objective: Identify proteomic and metabolomic biomarkers for Parkinson’s Disease (PD) progression diagnosis using statistical and machine learning (ML) approaches, leveraging data from cerebrospinal fluid (CSF)…
  • 2025 International Congress

    Reduced plasma levels of small HDL subfractions in advanced Parkinson’s disease

    CM. Chen, KH. Chang, ML. Cheng (Taoyuan, Taiwan)

    Objective: The present study investigated alterations of circulatory lipoprotein profiles, including cholesterol, triglycerides (TGs), phospholipids (PLs) and apolipoproteins (Apo) in lipoprotein subfractions, in Parkinson's disease…
  • 2025 International Congress

    Plasma Biomarkers Predict Clinical Outcomes in Individuals with Neuronal α-Synuclein Disease and Amyloid-β Co-Pathology

    S. Lorkiewicz, C. Abdelnour, A. Smith, N. Siddiqui, L. Montoliu-Gaya, E. Wilson, N. Ashton, B. Arslan, M. Plastini, C. Young, J. Winer, M. Shahid-Besanti, H. Vossler, V. Ramirez, G. Kerchner, K. Andreasson, V. Henderson, T. Montine, L. Tian, E. Mormino, H. Zetterberg, K. Poston (Gothenburg, Sweden)

    Objective: We examined whether the plasma biomarkers pTau181, pTau217, GFAP, NfL, and Aβ42/40 are associated with cognitive, functional, and motor outcomes in individuals with neuronal…
  • 2025 International Congress

    Classification of Medication State in Parkinson’s Disease Patients with and without Fluctuations using Facial Videos

    I. Boura, V. Skaramagkas, G. Karamanis, I. Kyprakis, D. Fotiadis, Z. Kefalopoulou, M. Tsiknakis, C. Spanaki (Heraklion, Crete, Greece)

    Objective: This study presents a unique, interpretable Dual-Stream Transformer model for classifying medication state in patients with Parkinson’s disease (PD) using facial videos. Background: Recent…
  • 2025 International Congress

    Enhancing Step Detection in Real-World Gait

    A. Ena, C. Mazzà, E. Bartholomé, C. Bernasconi, S. Belachew, ó. Reyes (Basel, Switzerland)

    Objective: To enhance accuracy and applicability of algorithms for step detection obtained from free-living gait accelerometer data in individuals with Parkinson’s Disease (PD). Background: When…
  • 2025 International Congress

    A Qualitative Approach to Extract Diagnostic Patterns of Cognitive Impairment in Parkinson’s Disease

    A. Eubank, A. Thatikala, M. Garza, H. Khan, T. Virmani, R. Dhall, J. Talburt, L. Larson-Prior, F. Prior (Little Rock, USA)

    Objective: This study distilled patterns of patient performance recognized by clinical professionals in people with Parkinson’s disease (PD) and cognitive impairment on the Montreal Cognitive…
  • 2025 International Congress

    Aberrations in Voluntary Thought Initiation: Parallels to Motor Freezing in Basal Ganglia Dysfunction

    S. Shugar, N. Choudhury, D. Nolasco, B. Carr (Gainesvile, USA)

    Objective: To explore the neurophysiological basis of impaired volitional thought initiation focusing on dorsal caudate dysfunction, aberrant pallidal-thalamic inhibition, and impaired corticostriatal integration. Background: While…
  • 2025 International Congress

    Cerebral Vasoreactivity and Neuropsychiatric Features in Parkinson’s disease.

    M. Cansino Torres, D. Ortiz Zacarias, S. Castillo Torres, R. Lopez Soto, J. Trejo Ayala, A. Infante Valenzuela, F. Gongora Rivera, B. Chavez Luevanos, I. Estrada Bellmann (Monterrey, Mexico)

    Objective: To determine cerebral vasoreactivity (CVR) in Parkinson’s disease (PD) and its association with the neuropsychiatric features of the disease. Background: Non-motor symptoms in PD…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley